open access

Vol 14, No 5 (2018)
Review paper
Published online: 2019-02-15
Get Citation

Systemic treatments for advanced cutaneous melanoma — Cochrane Systematic Review 2018

Joanna Połowinczak-Przybyłek, Piotr Potemski
DOI: 10.5603/OCP.2018.0030
·
Oncol Clin Pract 2018;14(5):241-248.

open access

Vol 14, No 5 (2018)
REVIEW ARTICLES
Published online: 2019-02-15

Abstract

The results of the systematic review have the leading place in the hierarchy of clinical data reliability. They allow to extend the conclusions from individual studies to a larger population, minimizing the risk of systematic errors. Meta-analysis is the final step of the review of enough homogenous primary research that allow to quantitatively synthesize their results. In 2018, the Cochrane systematic review and data meta-analysis which assessed the effects of various systemic treatments of metastatic cutaneous melanoma were published. All relevant trials published up to October 2017 were included. This article introduces the assumptions of the meta-analysis and presents its results regarding the effectiveness of the most important systemic treatments of melanoma.

Abstract

The results of the systematic review have the leading place in the hierarchy of clinical data reliability. They allow to extend the conclusions from individual studies to a larger population, minimizing the risk of systematic errors. Meta-analysis is the final step of the review of enough homogenous primary research that allow to quantitatively synthesize their results. In 2018, the Cochrane systematic review and data meta-analysis which assessed the effects of various systemic treatments of metastatic cutaneous melanoma were published. All relevant trials published up to October 2017 were included. This article introduces the assumptions of the meta-analysis and presents its results regarding the effectiveness of the most important systemic treatments of melanoma.
Get Citation

Keywords

Cochrane meta-analysis; metastatic melanoma; anti-BRAF/anti-MEK therapy; immunotherapy

About this article
Title

Systemic treatments for advanced cutaneous melanoma — Cochrane Systematic Review 2018

Journal

Oncology in Clinical Practice

Issue

Vol 14, No 5 (2018)

Article type

Review paper

Pages

241-248

Published online

2019-02-15

DOI

10.5603/OCP.2018.0030

Bibliographic record

Oncol Clin Pract 2018;14(5):241-248.

Keywords

Cochrane meta-analysis
metastatic melanoma
anti-BRAF/anti-MEK therapy
immunotherapy

Authors

Joanna Połowinczak-Przybyłek
Piotr Potemski

References (20)
  1. Polski Instytut Evidence Based Medicine. http://ebm.org.pl/show.php?aid=15739&_tc=272C56A7C6FEB3D89BA5503840A57516 (dostęp z dnia 22.07.2018.).
  2. http://poland.cochrane.org/pl/jak-interpretować-przeglądy-systematyczne (dostęp z dnia 22.07.2018.).
  3. Bała M, Leśniak W, Jaeschke R. Proces przygotowywania przeglądów systematycznych, z uwzględnieniem przeglądów Cochrane. Polish Archives of Internal Medicine. 2015; 125(Special Issue): 16–25.
  4. Leśniak W, Bała M, Jaeschke R, et al. Od danych naukowych do praktycznych zaleceń – tworzenie wytycznych według metodologii GRADE. Polish Archives of Internal Medicine. 2015; 125(Special Issue): 26–41.
  5. https://poland.cochrane.org/pl/cochrane (dostęp z dnia 22.07.2018).
  6. Pasquali S, Hadjinicolaou AV, Chiarion Sileni V, et al. Systemic treatments for metastatic cutaneous melanoma. Cochrane Database Syst Rev. 2018; 2: CD011123.
  7. Robert C, Thomas L, Bondarenko I, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med. 2011; 364(26): 2517–2526.
  8. Ribas A, Kefford R, Marshall MA, et al. Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma. J Clin Oncol. 2013; 31(5): 616–622.
  9. Robert C, Long GV, Brady B, et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med. 2015; 372(4): 320–330.
  10. Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. N Engl J Med. 2015; 373(1): 23–34.
  11. Hauschild A, Grob JJ, Demidov LV, et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet. 2012; 380(9839): 358–365.
  12. McArthur GA, Chapman PB, Robert C, et al. Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study. Lancet Oncol. 2014; 15(3): 323–332.
  13. Gupta A, Love S, Schuh A, et al. DOC-MEK: a double-blind randomized phase II trial of docetaxel with or without selumetinib in wild-type BRAF advanced melanoma. Ann Oncol. 2014; 25(5): 968–974.
  14. Flaherty KT, Robert C, Hersey P, et al. METRIC Study Group. Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med. 2012; 367(2): 107–114.
  15. Robert C, Dummer R, Gutzmer R, et al. Selumetinib plus dacarbazine versus placebo plus dacarbazine as first-line treatment for BRAF-mutant metastatic melanoma: a phase 2 double-blind randomised study. The Lancet Oncology. 2013; 14(8): 733–740.
  16. Robert C, Karaszewska B, Schachter J, et al. Improved overall survival in melanoma with combined dabrafenib and trametinib. N Engl J Med. 2015; 372(1): 30–39.
  17. Long GV, Stroyakovskiy D, Gogas H, et al. Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial. Lancet. 2015; 386(9992): 444–451.
  18. Larkin J, Ascierto PA, Dréno B, et al. Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. N Engl J Med. 2014; 371(20): 1867–1876.
  19. Flaherty KT, Infante JR, Daud A, et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med. 2012; 367(18): 1694–1703.
  20. Połowinczak-Przybyłek J, Potemski P. Treatment of patients with advanced melanoma harboring the BRAF V600 mutation. Oncol Clin Pract. 2018; 14: 48–52.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl